Shu-Qin Yu

Shu-Qin Yu

Auto-generated profile, based on publicly available information

Shu-Qin Yu

Jiangsu Province Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing 210046, People's Republic of China

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 August 2011 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
XXXiaoxia Xie
Xiaoxia Xie
QTQing Tao
Qing Tao
YZYina Zou
Yina Zou
FZFengyi Zhang
Fengyi Zhang
MGMiao Guo
Miao Guo
SYShuqin Yu
Shuqin Yu

1 January 2017 in Drug Delivery
Verified
Journal Article
Open access
SQShan-Shan Qi
Shan-Shan Qi
JSJia-Hui Sun
Jia-Hui Sun
HYHao-Han Yu
Hao-Han Yu
SYShu-Qin Yu
Shu-Qin Yu
To achieve superior therapeutic efficacy, the combination chemotherapy using two or more anticancer drugs in clinical practice has been generally accepted as a feasible strategy. On account of the concept of combination chemotherapy, co-delivery of anticancer drugs with nanotechnology gradually becomes a desired strategy and one of the research frontiers on modern drug delivery. In recent years, nano drug co-delivery system (NDCDS), which loads at least two anticancer drugs with different physicochemical and pharmacological properties into a combination delivery system, has achieved rapid development. NDCDS synergistically inhibited the growth of the tumor compared with the free drugs. In this review, we highlighted the current state of co-delivery nanoparticles and the most commonly used nanomaterial, discussed challenges and strategies, and prospect future development.

1 March 2019 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
SQShanshan Qi
Shanshan Qi
LGLingyuan Guo
Lingyuan Guo
SYShuzhen Yan
Shuzhen Yan
RLRobert J. Lee
Robert J. Lee
SYShuqin Yu
Shuqin Yu
SCShuanglin Chen
Shuanglin Chen
Over recent decades, many studies have reported that hypocrellin A (HA) can eliminate cancer cells with proper irradiation in several cancer cell lines. However, the precise molecular mechanism underlying its anticancer effect has not been fully defined. HA-mediated cytotoxicity and apoptosis in human lung adenocarcinoma A549 cells were evaluated after photodynamic therapy (PDT). A temporal quantitative proteomics approach by isobaric tag for relative and absolute quantitation (iTRAQ) 2D liquid chromatography with tandem mass spectrometric (LC-MS/MS) was introduced to help clarify molecular cytotoxic mechanisms and identify candidate targets of HA-induced apoptotic cell death. Specific caspase inhibitors were used to further elucidate the molecular pathway underlying apoptosis in PDT-treated A549 cells. Finally, down-stream apoptosis-related protein was evaluated. Apoptosis induced by HA was associated with cell shrinkage, externalization of cell membrane phosphatidylserine, DNA fragmentation, and mitochondrial disruption, which were preceded by increased intracellular reactive oxygen species (ROS) generations. Further studies showed that PDT treatment with 0.08 µmol/L HA resulted in mitochondrial disruption, pronounced release of cytochrome c, and activation of caspase-3, -9, and -7. Together, HA may be a possible therapeutic agent directed toward mitochondria and a promising photodynamic anticancer candidate for further evaluation.

17 February 2010 in Analytical Chemistry
Verified
Journal Article
Closed access
DCDongxiao Chen
Dongxiao Chen
QWQian Wang
Qian Wang
JJJuan Jin
Juan Jin
PWPing Wu
Ping Wu
HWHui Wang
Hui Wang
CCChenxin Cai
Chenxin Cai

1 March 2017 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
HGHai-Tao Gao
Hai-Tao Gao
RXRun Xu
Run Xu
WCWei-Xin Cao
Wei-Xin Cao
LQLiang-Liang Qian
Liang-Liang Qian
MWMin Wang
Min Wang
SYShu-Qin Yu
Shu-Qin Yu

30 January 2011 in Carbohydrate Polymers
Verified
Journal Article
Closed access
JZJian Zeng
Jian Zeng
YRYong Ren
Yong Ren
CZChengliang Zhou
Chengliang Zhou
SYShuqin Yu
Shuqin Yu
WCWen-Hua Chen
Wen-Hua Chen